Hhlr Advisors, Ltd. I Mab Call Options Transaction History
Hhlr Advisors, Ltd.
- $2.42 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMAB
# of Institutions
41Shares Held
14.2MCall Options Held
10.2KPut Options Held
0-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$15.1 Million3.04% of portfolio
-
Candriam S.C.A.1.13MShares$4.1 Million0.02% of portfolio
-
Sg Americas Securities, LLC876KShares$3.17 Million0.01% of portfolio
-
International Biotechnology Trust PLC London, X0310KShares$1.12 Million0.14% of portfolio
-
Edbi Pte LTD Singapore, U0222KShares$804,1320.2% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $301M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...